ACCESS DB # 183556

FOR OFFICIAL USE ONLY *PLEASE PRINT CLEARLY*

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: Susanna Moore Examiner # : 82304 Date: 3/27/06
Art Unit: 1624 Phone Number: 2-9046 Serial Number: 10/783000
Location (Bldg/Room#): Rem 5831 (Mailbox #) Rem 5C18 Results Format Preferred (circle): (PAPER) DISK

****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following: MEP

Title of Invention: _____

Inventors (please provide full names): _____

_____

Earliest Priority Date: _____

Search Topic:
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*



****

STAFF USE ONLY

Searcher: _____
Searcher Phone #: _____
Searcher Location: _____
Date Searcher Picked Up: _____
Date Completed: _____
Searcher Prep & Review Time: _____
Online Time: _____

Type of Search

_____ NA Sequence (#)
_____ AA Sequence (#)
_____ Structure (#)
_____ Bibliographic
_____ Litigation.
_____ Fulltext.
_____ Other

Vendors and cost where applicable

_____ STN _____ Dialog
_____ Questel/Orbit _____ Lexis/Nexis
_____ Westlaw _____ WWW/Internet
___ In-house sequence systems
___ Commercial ___ Oligomer ___ Score/Length
___ Interference ___ SPDI ___ Encode/Transl
_____ Other (specify)

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Apr 2006 VOL 144 ISS 15
FILE LAST UPDATED: 2 Apr 2006 (20060402/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que stat l4
L1 STR



VAR G1=13-1 12-8/12-1 13-8
REP G2=(1-10) C
VAR G3=N/O/16-2 17-19/14-2 15-19
NODE ATTRIBUTES:
NSPEC IS RC AT 9
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY UNS AT 11
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E6 C AT 11

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE
L3 208 SEA FILE=REGISTRY SSS FUL L1
L4 27 SEA FILE=HCAPLUS ABB=ON PLU=ON L3

=> d l4 ibib abs hitstr 1-27

L4 ANSWER 1 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:165118 HCAPLUS
DOCUMENT NUMBER: 144:246354
TITLE: Signal transduction therapy with rationally designed kinase inhibitors
AUTHOR(S): Keri, Gyorgy; Orfi, Laszlo; Eros, Daniel; Hegymegi-Barakonyi, Balint; Szantai-Kis, Csaba; Horvath, Zoltan; Waczek, Frigyes; Marosfalvi, Jeno;

Szabadkai, Istvan; Pato, Janos; Greff, Zoltan; Hafenbradl, Doris; Daub, Henrik; Muller, Gerhard; Klebl, Bert; Ullrich, Axel
CORPORATE SOURCE: Vichem Chemie Research Ltd., Budapest, H-1022, Hung.
SOURCE: Current Signal Transduction Therapy (2006), 1(1), 67-95
CODEN: CSTTBV; ISSN: 1574-3624
PUBLISHER: Bentham Science Publishers Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Signal transduction therapy has become one of the most important areas of drug research. Signaling disorders represent a major cause for the pathol. states and many of the recently identified validated target mols. of drug research are signal transduction related macromols., mostly kinases. Rational drug design is aimed to achieve the selective inhibition of distinct pathol. relevant signaling enzymes or receptors. In the previous years, the concept of rational drug design has been expanded for a complex process including pathomechanism-based target selection, target validation, structural biol., mol. modeling, structure-activity relationships, pharmacophore-based compound selection and pharmacol. optimization. The two main branches of the chemical rational drug design are structure-based design and ligand-based design. Some important examples for the application of 3D structure-based rational drug design in the development of clin. relevant kinase inhibitors are presented. The Nested Chemical Library (NCL) technol. is a ligand-based design approach and relies on a knowledge-based approach, where focused libraries around published leads and selected cores are used to generate extended pharmacophore models (Prediction Oriented QSAR). NCL was designed on the platform of a diverse kinase inhibitor library, consisting of small mol. heterocycles, which are organized around 108 core structures. Some examples for testing the library on various targets and Prediction Oriented QSAR models will also be presented. The core elements of the kinase family-biased masterkey concept are the so-called privileged structures that emerge from a sophisticated mol. design and optimization process that encodes for a target family-wide structural commonality in ligand binding. The combination of a kinase family-wide imprinted commonality with addnl. structural fragments in the mol. periphery of a once established privileged structure allows to synthesize highly active and selective kinase inhibitors. In addition, several kinase inhibitors in preclin. or clin. development and application of 3D structure based rational drug design in the development of clin. relevant kinase inhibitors are reviewed.
IT **497839-62-0**, AEE 788
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(signal transduction therapy with rationally designed kinase inhibitors)
RN 497839-62-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

were Lovo (colon tumor), KB (nasopharyngeal), and HT29 (colon tumor), whereas the resistant cell lines were MKN 45 (gastric tumor), Calu 6 (lung tumor), and PC3 (prostate tumor). Expression profiles were determined by measuring RNA expression on the Affymetrix microarray platform and confirmed using RT-PCR. Preferred genes include any one of NES, GSPT2, ETR101, TAZ, CHST7, DNAJC3, NPAS2, PIN1, TCEA2, VAMP4, DAPK1, DAPK2, MLLT3, TNNC1, KIAA0931, ACOX2, EMP1, SLC20A1, SPRY2, or PGM1.

IT **497839-62-0**, AEE788
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gene expression markers for selection of erbB receptor drugs for treatment of tumors)
RN 497839-62-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:31415 HCAPLUS
DOCUMENT NUMBER: 144:108353
TITLE: Preparation of pyrrolo[2,3-d]pyrimidines that modulate ACK1 and LCK activity for use against cancer
INVENTOR(S): Farthing, Christopher N.; Faulder, Paul; Frenkel, Alexander David; Harrison, Martin James; Jiao, Xianyun; Kayser, Frank; Kopecky, David J.; Liu, Jinqian; Lively, Sarah E.; Sharma, Rajiv; Shuttleworth, Stephen Joseph
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006004703	A2	20060112	WO 2005-US22836	20050629
WO 2006004703	A3	20060309		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,



REFERENCE COUNT: 224 THERE ARE 224 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:75312 HCAPLUS
DOCUMENT NUMBER: 144:164225
TITLE: Gene expression markers for selection of erbB receptor drugs for treatment of tumors
INVENTOR(S): Hudson, Kevin; South, Marie Caroline; Marshall, Gayle; Sam, Mehran
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006008526	A2	20060126	WO 2005-GB2852	20050720

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:		
US 2004-590357P	P	20040723
US 2004-619027P	P	20041018

AB The invention relates to a method of selecting a mammal having or suspected of having a tumor for treatment with an erbB receptor drug which comprises testing a biol. sample from the mammal for expression of any one of certain specific genes to predict an increased likelihood of response to the erbB receptor drug. Genes useful to predict response to erbB receptor drugs were identified based on studies with tumors either sensitive to gefitinib or resistant to gefitinib, but the findings are applicable to erbB receptor drugs in general. The sensitive cell lines

NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,
KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM

US 2006040965 A1 20060223 US 2005-169313 20050629
PRIORITY APPLN. INFO.: US 2004-583682P P 20040629
OTHER SOURCE(S): MARPAT 144:108353
GI



I



II

AB Pyrrolo[2,3-d]pyrimidines (shown as I; variables defined below; e.g. (5,6-Diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)[2-(morpholin-4-yl)ethyl]amine (shown as II)) that modulate the action of ACK1 and LCK, and related compns. methods for treating ACK1- and LCK-mediated diseases like cancer are described. Activities against ACK1 and LCK are tabulated for .apprx.40 examples of I. For I: R1 is OR5, -SR5, or NHR5; R2 and R3 independently are (un)substituted aryl, (un)substituted heteroaryl, (un)substituted cycloalkyl, (un)substituted cycloheteroalkyl, (un)substituted arylalkyl, (heteroaryl)alkyl, substituted (heteroaryl)alkyl, (cycloalkyl)alkyl, substituted (cycloalkyl)alkyl, (cycloheteroalkyl)alkyl, or substituted (cycloheteroalkyl)alkyl; R4 is H, (un)substituted alkyl, (un)substituted alkylcarbonyl, (un)substituted arylcarbonyl, (un)substituted arylalkylcarbonyl, (un)substituted alkylsulfonyl, (un)substituted arylsulfonyl, (un)substituted arylalkylsulfonyl, (un)substituted trialkylsilyl, (un)substituted triarylalkylsilyl, formyl, (un)substituted diarylthiophosphinyl; and R5 is a (cycloheteroalkyl)alkyl or substituted (cycloheteroalkyl)alkyl moiety, wherein the cycloheteroalkyl portion of said moiety is a saturated ring. Although the methods of preparation are not claimed, prepns. and/or characterization data for .apprx.40 examples of I are included. For example, II was prepared in 4 steps starting with preparation of 2-amino-1-(2,4-dimethoxybenzyl)-4,5-diphenyl-1H-pyrrole-3-carbonitrile from benzoin, 2,4-dimethoxybenzylamine, and malononitrile and involving [7-(2,4-dimethoxybenzyl)-5,6-diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine [7-(2,4-dimethoxybenzyl)-5,6-diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl][2-(morpholin-4-yl)ethyl]amine and addnl. intermediates.

IT **873079-00-6P**, N-Methyl-4-[5-phenyl-4-[[((S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzamide
873079-02-8P, N,N-Dimethyl-4-[5-phenyl-4-[[((S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzamide

873079-03-9P, (Morpholin-4-yl)[4-[5-phenyl-4-[[((S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methanone **873079-04-0P**, N-Cyclopropyl-4-[5-phenyl-4-[[((S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzamide **873079-05-1P**, N-(2-Methoxyethyl)-4-[5-phenyl-4-[[((S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzamide **873079-06-2P**, N-[2-(Morpholin-4-yl)ethyl]-4-[5-phenyl-4-[[((S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzamide **873079-07-3P**, N-(2-Dimethylaminoethyl)-4-[5-phenyl-4-[[((S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrrolo[2,3-d]pyrimidines that modulate ACK1 and LCK activity for use against cancer)

RN 873079-00-6 HCAPLUS
CN Benzamide, N-methyl-4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 873079-02-8 HCAPLUS
CN Benzamide, N,N-dimethyl-4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 873079-03-9 HCAPLUS
CN Morpholine, 4-[4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 873079-04-0 HCAPLUS
CN Benzamide, N-cyclopropyl-4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 873079-05-1 HCAPLUS
CN Benzamide, N-(2-methoxyethyl)-4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 873079-06-2 HCAPLUS
CN Benzamide, N-[2-(4-morpholinyl)ethyl]-4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 873079-07-3 HCAPLUS
CN Benzamide, N-[2-(dimethylamino)ethyl]-4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1213903 HCAPLUS
DOCUMENT NUMBER: 144:16632
TITLE: Simultaneous Inhibition of EGFR, VEGFR, and Platelet-Derived Growth Factor Receptor Signaling Combined with Gemcitabine Produces Therapy of Human Pancreatic Carcinoma and Prolongs Survival in an Orthotopic Nude Mouse Model
AUTHOR(S): Yokoi, Kenji; Sasaki, Takamitsu; Bucana, Corazon D.; Fan, Dominic; Baker, Cheryl H.; Kitadai, Yasuhiko; Kuwai, Toshio; Abbruzzese, James L.; Fidler, Isaiah J.
CORPORATE SOURCE: Departments of Cancer Biology and Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
SOURCE: Cancer Research (2005), 65(22), 10371-10380
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Although gemcitabine has been approved as the first-line chemotherapeutic reagent for pancreatic cancer, its response rate is low and average survival duration is still only marginal. Because epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR) modulate tumor progression, we hypothesized that inhibition of phosphorylation of all three on tumor cells, tumor-associated endothelial cells, and stroma cells would improve the treatment efficacy of gemcitabine in an orthotopic pancreatic tumor model in nude mice and prolong survival. We implanted

L3.6pl, a human pancreatic cancer cell, in the pancreas of nude mice. We found that tumor-associated endothelial cells in this model highly expressed phosphorylated EGFR, VEGFR, and PDGFR. Oral administration of AEE788, a dual tyrosine kinase inhibitor against EGFR and VEGFR, decreased phosphorylation of EGFR and VEGFR. PDGFR phosphorylation was inhibited by STI571. Although i.p. injection of gemcitabine did not inhibit tumor growth, its combination with AEE788 and STI571 produced >80% inhibition of tumor growth and prolonged survival in parallel with increases in number of tumor cells and tumor-associated endothelial cell apoptosis, decreased microvascular d., decreased proliferation rate, and prolonged survival. STI571 treatment also decreased pericyte coverage on tumor-associated endothelial cells. Thus, inhibiting phosphorylation of EGFR, VEGFR, and PDGFR in combination with gemcitabine enhanced the efficacy of gemcitabine, resulting in inhibition of exptl. human pancreatic cancer growth and significant prolongation of survival.

IT **497839-62-0**, AEE 788
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(simultaneous inhibition of EGFR, VEGFR, and PDGFR signaling combined with gemcitabine for pancreatic carcinoma)

RN 497839-62-0 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1201285 HCAPLUS

DOCUMENT NUMBER: 144:226695

TITLE: Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice

AUTHOR(S): Yazici, S.; Kim, S. J.; Busby, J. E.; He, J.; Thaker, P.; Yokoi, K.; Fan, D.; Fidler, I. J.

CORPORATE SOURCE: Department of Cancer Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

SOURCE: Prostate (New York, NY, United States) (2005), 65(3), 203-215
CODEN: PRSTDS; ISSN: 0270-4137

PUBLISHER: Wiley-Liss, Inc.

DOCUMENT TYPE: Journal
LANGUAGE: English

AB Background. Androgen-independent prostate cancer (PCa) may be susceptible to modulation of the tumor microenvironment. We determined whether a dual tyrosine kinase inhibitor (AEE788) of the epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) combined with chemotherapy can produce therapy of human PCa in nude mice. Methods. PC-3MM2 human PCa cells were injected into the prostate of nude mice. Three days later, the mice were randomized into four groups: saline control, paclitaxel, AEE788, and AEE788 and paclitaxel. The mice were treated for 5 wk and necropsied. Tumor incidence, weight, and incidence of lymph node metastasis were recorded. Tumor tissue was analyzed immunohistochem. Results. Treatment of mice with AEE788 or AEE788 plus paclitaxel significantly decreased tumor incidence, total tumor weight, and incidence of lymph node metastasis. AEE788 treatment alone or in combination with paclitaxel inhibited the phosphorylation of EGF-R and VEGF-R on tumor cells and tumor-associated endothelial cells. Therapeutic efficacy correlated with an increase in apoptosis of tumor cells and tumor-associated endothelial cells. Conclusion. Blockade of EGF-R and VEGF-R signaling pathways coupled with chemotherapy suppressed the progressive growth and metastasis of human PCa cells growing orthotopically in nude mice.

IT **497839-62-0**, AEE 788
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dual tyrosine kinase inhibitor AEE788 alone or with paclitaxel inhibited phosphorylation of EGF-R and VEGF-R and raised apoptosis of tumor cells and tumor-associated endothelial cells in prostate of mouse with growing human PCa PC-3MM2 cell)

RN 497839-62-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1004423 HCAPLUS
DOCUMENT NUMBER: 143:312080
TITLE: Artificial blood vessel for delivering therapeutic agents
INVENTOR(S): Bhat, Vinayak D.; Yan, John

PATENT ASSIGNEE(S): Avantec Vascular Corp., USA
SOURCE: U.S. Pat. Appl. Publ., 52 pp., Cont.-in-part of U.S. Ser. No. 206,807.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005203612	A1	20050915	US 2003-607836	20030627
US 2002114823	A1	20020822	US 2001-782927	20010213
US 6471980	B2	20021029		
US 7018405	B2	20060328	US 2001-782804	20010213
US 2002082679	A1	20020627	US 2001-2595	20011101
US 2003083646	A1	20030501	US 2001-17500	20011214
US 2003050692	A1	20030313	US 2002-206807	20020725
US 2003017190	A1	20030123	US 2002-242334	20020911
US 6858221	B2	20050222		
WO 2004010900	A1	20040205	WO 2003-US20492	20030627
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003261100	A1	20040216	AU 2003-261100	20030627
JP 2005533604	T2	20051110	JP 2004-524538	20030627

PRIORITY APPLN. INFO.:

US 2000-258024P	P	20001222
US 2001-782804	A2	20010213
US 2001-782927	A2	20010213
US 2001-783253	A2	20010213
US 2001-783254	A2	20010213
US 2001-308381P	P	20010726
US 2001-2595	A2	20011101
US 2001-17500	A2	20011214
US 2002-347473P	P	20020110
US 2002-355317P	P	20020207
US 2002-370703P	P	20020406
US 2002-206807	A2	20020725
US 2002-404624P	P	20020819
US 2003-454146P	P	20030311
US 2003-472536P	P	20030521
WO 2003-US20492	W	20030627

AB Devices and methods for reducing, inhibiting, or treating restenosis and hyperplasia after intravascular intervention are provided. In particular, the present invention provides luminal prostheses which allow for sustained or controlled release of at least one therapeutic capable agent with increased efficacy to selected locations within a patient's vasculature to reduce restenosis. An intraluminal prosthesis may comprise an expandable structure and a source adjacent the expandable structure for releasing the therapeutic capable agent into a body lumen to reduce smooth muscle cell proliferation.

IT **497839-62-0**, AEE 788

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(artificial blood vessel for delivering therapeutic agents)
RN 497839-62-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 7 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:902897 HCAPLUS
DOCUMENT NUMBER: 143:248404
TITLE: Preparation of 7H-pyrrolopyrimidine derivatives for the treating a disease which responds to an inhibition of a protein tyrosine kinase
INVENTOR(S): Caravatti, Giorgio; Vaupel, Andrea
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005077951	A2	20050825	WO 2005-EP1635	20050217
WO 2005077951	A3	20060302		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2004-3606 A 20040218
OTHER SOURCE(S): MARPAT 143:248404
GI



I

AB The title compds. I [R1, R2 = H, halo, alkyl, etc.; or NR1R2 = (un)substituted N-heterocycle; Y = X(R3)n, C(R3)(R3)A (wherein X = alkyl, amino, amido, carbonyl; A = hydroxy, amino, halo, alkyl; R3 = alkyl, alkoxy, carbonyl, etc.; n = 1-2)], useful for the treatment especially of a proliferative disease, such as a tumor, were prepared and formulated. E.g., a multi-step synthesis of I [R1 = Me; R2 = Pr; Y = 4-methylpiperazin-1-ylmethyl], starting from Et 4-(4-chloro-7H-pyrrolo[2,3]pyrimidin-6-yl)benzoate, was given. The compds. I were tested against BcrAbl, c-Abl, c-Raf-1, HER-1, HER-2 and VEGF receptor (KDR). Specific data were given for representative compds. I. The invention also relates to pharmaceutical compns. comprising such derivs. I and to the use of such derivs. - alone or in combination with one or more other pharmaceutically active compds. - for the preparation of pharmaceutical compns.

IT **863306-84-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 7H-pyrrolopyrimidine derivs. as protein tyrosine kinase inhibitors)

RN 863306-84-7 HCAPLUS

CN Piperazine, 1-[4-[4-(cyclopropylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]benzoyl]-4-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:823692 HCAPLUS

DOCUMENT NUMBER: 143:229883

TITLE: Preparation of pyrrolopyrimidines for treating proliferative diseases

INVENTOR(S): Caravatti, Giorgio; Traxler, Peter; Esser, Thomas; He, Handan

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005075460	A2	20050818	WO 2005-EP876	20050128

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-540034P P 20040129
OTHER SOURCE(S): CASREACT 143:229883; MARPAT 143:229883
GI



I



II

AB The present invention relates to a compound I [R1 = heterocyclyl, (un)substituted aryl; G = alkylene, C(O), or alkyleneC(O) wherein the carbonyl group is attached to the piperazine moiety; Q = NH or O, with the proviso that Q = O if G = C(O) or alkyleneC(O); and X is either not present or alkylene, with the proviso that a heterocyclic radical R1 is bonded via a ring carbon atom if X is not present], which is useful for treating anti-proliferative diseases. E.g., a 2-step synthesis of (R)-II, starting from {6-[4-(chloromethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-[(R)-1-phenylethyl]amine and N-BOC-piperazine, was given. The compds. I

are effective as protein tyrosine kinase inhibitors. For example, the compds. I inhibit EGF-R tyrosine kinase activity by 50% in a concentration of from 0.0005 to 0.5 μM, especially from 0.001 to 0.1 μM.

IT **803706-07-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolopyrimidines as protein tyrosine kinase inhibitors for treating proliferative diseases)

RN 803706-07-2 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1R)-1-phenylethyl]-6-[4-(1-piperazinylmethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **803706-08-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolopyrimidines as protein tyrosine kinase inhibitors for treating proliferative diseases)

RN 803706-08-3 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 9 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:585333 HCAPLUS
DOCUMENT NUMBER: 143:399003
TITLE: Antivascular Therapy for Orthotopic Human Ovarian Carcinoma through Blockade of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptors
AUTHOR(S): Thaker, Premal H.; Yazici, Sertac; Nilsson, Monique B.; Yokoi, Kenji; Tsan, Rachel Z.; He, Junqin; Kim, Sun-Jin; Fidler, Isaiah J.; Sood, Anil K.
CORPORATE SOURCE: Departments of Cancer Biology and Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
SOURCE: Clinical Cancer Research (2005), 11(13), 4923-4933 CODEN: CCREF4; ISSN: 1078-0432
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB PURPOSE: We determined whether the administration of the tyrosine kinase inhibitor, AEE788, which targets the epidermal growth factor receptor and the vascular endothelial growth factor receptor, alone or in combination with paclitaxel, can inhibit progressive growth of human ovarian carcinoma in the peritoneal cavity of female nude mice. Exptl. Design: Western blot anal. and immunohistochem. anal. identified the optimal dose and schedule of AEE788 therapy. In several different expts., paclitaxel-sensitive and paclitaxel-resistant human ovarian carcinoma cells were injected into the peritoneal cavity of nude mice. Seven days later, treatment with saline (control), AEE788 alone, paclitaxel alone, or a combination of AEE788 and paclitaxel began and continued for 45 days when the mice were necropsied. In independent survival expts., the mice were necropsied when they became moribund. RESULTS: Oral administration of AEE788 inhibited phosphorylation of the epidermal growth factor receptor and vascular endothelial growth factor receptor for up to 48 h. Treatment with AEE788 plus paclitaxel significantly reduced tumor weight and increased survival of mice implanted with paclitaxel-sensitive cell lines compared with control mice or mice treated with AEE788 alone or paclitaxel alone. In mice implanted with paclitaxel-resistant cells, the combination therapy also significantly reduced tumor weight but did not prolong survival. The combination therapy induced apoptosis of both tumor cells and tumor-associated endothelial cells. CONCLUSIONS: The administration of AEE788 and paclitaxel inhibits the progression of human ovarian carcinoma in the peritoneal cavity of female nude mice, in part, by inducing apoptosis of tumor-associated endothelial cells.

IT **497839-62-0**, AEE 788
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral AEE788 infusion inhibited VEGFR, EGFR phosphorylation and in combination with i.p paclitaxel reduced tumor weight, induced apoptosis in mouse with HeyA8, SkOVip1 cell and increased survival of mouse with paclitaxel-sensitive cell line)

RN 497839-62-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:467276 HCAPLUS
DOCUMENT NUMBER: 143:71224
TITLE: Antivascular Therapy of Human Follicular Thyroid Cancer Experimental Bone Metastasis by Blockade of Epidermal Growth Factor Receptor and Vascular Growth Factor Receptor Phosphorylation
AUTHOR(S): Younes, Maher Nabil; Yigitbasi, Orhan Gazi; Park, Young Wook; Kim, Sun-Jin; Jasser, Samar A.; Hawthorne, Valerie Stone; Yazici, Yasemin Dakak; Mandal, Mahitosh; Bekele, Benjamin Nebiyou; Bucana, Corazon D.; Fidler, Isaiah J.; Myers, Jeffrey N.
CORPORATE SOURCE: Department of Head and Neck Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 66030-4009, USA
SOURCE: Cancer Research (2005), 65(11), 4716-4727
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Patients suffering from bone metastases of follicular thyroid carcinoma (FTC) have a poor prognosis because of the lack of effective treatment strategies. The overexpression of epidermal growth factor receptor (EGFR) associated with increased vascularity has been implicated in the pathogenesis of FTC and subsequent bone metastases. The authors hypothesized that inhibiting the phosphorylation of the EGFR and vascular endothelial growth factor receptor (VEGFR) by AEE788, a dual tyrosine kinase inhibitor of EGFR and VEGFR, in combination with paclitaxel would inhibit exptl. FTC bone lesions and preserve bone structure. The authors tested this hypothesis using the human WRO FTC cell line. In culture, AEE788 inhibited the EGF-mediated phosphorylation of EGFR, VEGFR2, mitogen-activated protein kinase, and Akt in culture. AEE788, alone and in combination with paclitaxel, inhibited cell growth and induced apoptosis. When WRO cells were injected into the tibia of nude mice, tumor and endothelial cells within the lesions expressed phosphorylated EGFR, VEGFR, Akt, and mitogen-activated protein kinase that were inhibited by the oral administration of AEE788. Therapy consisting of orally given AEE788 and i.p. injected paclitaxel induced a high level of apoptosis in tumor-associated endothelial cells and tumor cells with the inhibition of tumor growth in the bone and the preservation of bone structure. Collectively, these data show that blocking the phosphorylation of EGFR

and VEGFR with AEE788 combined with paclitaxel can significantly inhibit exptl. human FTC in the bone of nude mice.

IT **497839-62-0**, AEE 788
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antivascular therapy of human follicular thyroid cancer exptl. bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation)

RN 497839-62-0 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:391205 HCAPLUS
DOCUMENT NUMBER: 143:259101
TITLE: Multiple target molecules of tyrosine kinase inhibitors including EGFR
AUTHOR(S): Yano, Seiji
CORPORATE SOURCE: Tokushima University, Japan
SOURCE: Bunshi Kokyukibyo (2005), 9(2), 146-149
CODEN: BUKOFC; ISSN: 1342-436X
PUBLISHER: Sentan Igakusha
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Japanese

AB A review. Multiple target mols. of tyrosine kinase inhibitors including EGFR in the treatment of cancer is reviewed with ZD6474, AEE788, GW572016, and CI-1033 as examples. The comparison of multiple and single target therapy is also discussed.

IT **497839-62-0**, AEE 788
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(multiple target mols. of tyrosine kinase inhibitors including EGFR)

RN 497839-62-0 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 12 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:375699 HCAPLUS
DOCUMENT NUMBER: 142:456524
TITLE: Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model
AUTHOR(S): Yokoi, Kenji; Thaker, Premal H.; Yazici, Sertac; Rebhun, Robert R.; Nam, Do-Hyun; He, Junqin; Kim, Sun-Jin; Abbruzzese, James L.; Hamilton, Stanley R.; Fidler, Isaiah J.
CORPORATE SOURCE: Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
SOURCE: Cancer Research (2005), 65(9), 3716-3725
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We studied growth factors and their receptors in tumor cells and tumor-associated endothelial cells as the therapeutic targets in colon cancer. Immunohistochem. anal. of 13 surgical specimens of human colon adenocarcinoma revealed that both tumor cells and tumor-associated endothelial cells in 11 of the 13 specimens expressed the epidermal growth factor (EGF), transforming growth factor α (TGF-α), EGF receptor (EGFR), phosphorylated EGFR (pEGFR), vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR), and phosphorylated VEGFR (pVEGFR). HT29 human colon cancer cells growing orthotopically in the cecum of nude mice expressed a high level of EGF, EGFR, pEGFR, VEGF, VEGFR, and pVEGFR. Double-immunofluorescence staining found that tumor-associated mouse endothelial cells also expressed pEGFR and pVEGFR. Tumors in mice treated for 5 wk with oral AEE788 (an inhibitor of EGFR and VEGFR tyrosine kinase) as a single agent or with CPT-11 alone were smaller (>50%) than those in control mice. Mice treated with the combination of AEE788 and CPT-11 had significantly smaller tumors ($P < 0.01$) and complete inhibition of lymph node metastasis. AEE788 alone or in combination with CPT-11 inhibited pEGFR, pVEGFR, and phosphorylated Akt expression on tumor-associated endothelial cells as well as on tumor cells. The combination therapy also significantly decreased microvessel d. and tumor cell proliferation and increased the level of apoptosis in both tumor cells and tumor-associated endothelial cells. Collectively, these data suggest that the dual inhibition of EGFR and VEGFR signaling pathways in tumor cells and tumor-associated endothelial cells in combination with chemotherapy can

provide a new approach to the treatment of colon cancer.

IT **497839-62-0**, AEE 788
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model)

RN 497839-62-0 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:313324 HCAPLUS

DOCUMENT NUMBER: 143:90368

TITLE: Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788

AUTHOR(S): Kim, Seungwon; Schiff, Bradley A.; Yigitbasi, Orhan G.; Doan, Dao; Jasser, Samar A.; Bekele, B. Nebiyou; Mandal, Mahitosh; Myers, Jeffrey N.

CORPORATE SOURCE: Departments of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

SOURCE: Molecular Cancer Therapeutics (2005), 4(4), 632-640
CODEN: MCTOCF; ISSN: 1535-7163

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human malignancies with a mean survival of only 6 mo. The poor prognosis of patients with ATC reflects the current lack of curative therapeutic options and the need for development of novel therapeutic strategies. In this study, we report the results of a preclin. study of AEE788, a dual inhibitor of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) tyrosine kinases, against ATC. AEE788 was able to inhibit the proliferation and induce apoptosis of ATC cell lines in vitro. Administration of AEE788, alone and in combination with paclitaxel, to athymic nude mice bearing s.c. ATC xenografts inhibited the growth of ATC xenografts by 44% and 69%, resp., compared with the control group. Furthermore, tumors from mice treated with

AEE788, alone and in combination with paclitaxel, showed increase in apoptosis of tumor cells by .apprx. 6- and 8-fold, resp., compared with the control group. The microvessel d. within the ATC xenografts was decreased by > 80% in the mice treated with AEE788 alone and in combination with paclitaxel compared with the control group. Lastly, immunofluorescence microscopy showed the inhibition of EGFR autophosphorylation on the tumor cells as well as the inhibition of VEGFR-2 autophosphorylation on tumor endothelium. Considering the fact that curative options seldom exist for patients with ATC, concurrent inhibition of EGFR and VEGFR tyrosine kinases seems to be a valid and promising anticancer strategy for these patients.

IT **497839-62-0**, AEE 788
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapy of anaplastic thyroid carcinoma with AEE788)

RN 497839-62-0 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:206832 HCAPLUS

DOCUMENT NUMBER: 143:517

TITLE: AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice

AUTHOR(S): Park, Young Wook; Younes, Maher N.; Jasser, Samar A.; Yigitbasi, Orhan G.; Zhou, Ge; Bucana, Corazon D.; Bekele, Benjamin N.; Myers, Jeffrey N.

CORPORATE SOURCE: Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

SOURCE: Clinical Cancer Research (2005), 11(5), 1963-1973
CODEN: CCREF4; ISSN: 1078-0432

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We investigated whether concomitant blockade of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) signaling pathways by AEE788, a dual inhibitor of EGFR and VEGFR tyrosine kinases, would inhibit the growth of cutaneous squamous cell

carcinoma (SCC) cells and human cutaneous cancer xenografts in nude mice. We examined the effects of AEE788 on the phosphorylation of EGFR and VEGFR-2 in cutaneous SCC cells expressing EGFR and VEGFR-2 and cutaneous SCC cell growth and apoptosis. We assessed the in vivo antitumor effects of AEE788 in a xenograft model in nude mice. AEE788 (50 mg/kg) was given orally thrice weekly to mice that had been s.c. injected with CoLo16 tumor cells. Mechanisms of in vivo AEE788 activity were determined by immunohistochem. anal. Treatment of cutaneous SCC cells with AEE788 led to dose-dependent inhibition of EGFR and VEGFR-2 phosphorylation, growth inhibition, and induction of apoptosis. In mice treated with AEE788, tumor growth was inhibited by 54% at 21 days after the start of treatment compared with control mice ($P < 0.01$). Immunohistochem. anal. revealed that AEE788 inhibited phosphorylation of EGFR and VEGFR and induced apoptosis of tumor cells and tumor-associated endothelial cells. In addition to inhibiting cutaneous cancer cell growth by blocking EGFR and VEGFR signaling pathways in vitro, AEE788 inhibited in vivo tumor growth by inducing tumor and endothelial cell apoptosis.

IT **497839-62-0**, AEE 788
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(AEE788 inhibited phosphorylation of EGFR and VEGFR and induced apoptosis in human CoLo16, SRB1, SRB12 cutaneous SCC cells and in mouse model xenografted with CoLo16 cutaneous SCC cell line with inhibition of tumor growth, prolonged survival)

RN 497839-62-0 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:158541 HCAPLUS
DOCUMENT NUMBER: 142:254570
TITLE: Dosing schedule for erbB2 anticancer agents
INVENTOR(S): Bhattacharya, Samit Kumar; Connell, Richard Damian; Moyer, James Dale; Jani, Jitesh Pranlal; Noe, Dennis Alan; Steyn, Stefanus Johannes
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016347	A1	20050224	WO 2004-IB2580	20040806
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004264726	A1	20050224	AU 2004-264726	20040806
US 2005119288	A1	20050602	US 2004-919831	20040817
PRIORITY APPLN. INFO.:			US 2003-495919P P	20030818
			WO 2004-IB2580 W	20040806

OTHER SOURCE(S): MARPAT 142:254570

AB The invention discloses methods for treating overexpression of erbB2 in a mammal in need of treatment by administering a therapeutically effective amount of a first inhibitor of an erbB2 receptor and then, after an interval of less than 24 h, administering to the mammal 1-6 therapeutically effective amts. of the same or different inhibitor of the erbB2 receptor. The invention also discloses a slow daily infusion of the erbB2 inhibitor. The overexpression of the erbB2 receptor can result in abnormal cell growth and lead to cancer. By the methods of the invention, the efficacy and safety of the inhibitors is increased. The invention further discloses kits for facilitating the dose administration method of the invention.

IT **497839-62-0**, AEE 788
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(erbB2 anticancer agent dosing schedule)

RN 497839-62-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:45892 HCAPLUS
DOCUMENT NUMBER: 142:232698
TITLE: Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
AUTHOR(S): Goudar, Ranjit K.; Shi, Qing; Hjelmeland, Mark D.; Keir, Stephen T.; McLendon, Roger E.; Wikstrand, Carol J.; Reese, Elizabeth D.; Conrad, Charles A.; Traxler, Peter; Lane, Heidi A.; Reardon, David A.; Cavenee, Webster K.; Wang, Xiao-Fan; Bigner, Darell D.; Friedman, Henry S.; Rich, Jeremy N.
CORPORATE SOURCE: Department of Pathology, Duke University Medical Center, Durham, NC, USA
SOURCE: Molecular Cancer Therapeutics (2005), 4(1), 101-112
CODEN: MCTOCF; ISSN: 1535-7163
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Malignant gliomas are highly lethal tumors that display striking genetic heterogeneity. Novel therapies that inhibit a single mol. target may slow tumor progression, but tumors are likely not dependent on a signal transduction pathway. Rather, malignant gliomas exhibit sustained mitogenesis and cell growth mediated in part through the effects of receptor tyrosine kinases and the mammalian target of rapamycin (mTOR). AEE788 is a novel orally active tyrosine kinase inhibitor that decreases the kinase activity associated with the epidermal growth factor receptor and, at higher concns., the vascular endothelial growth factor receptor 2 (kinase domain region). RAD001 (everolimus) is an orally available mTOR inhibitor structurally related to rapamycin. We hypothesized that combined inhibition of upstream epidermal growth factor receptor and kinase domain region receptors with AEE788 and inhibition of the downstream mTOR pathway with RAD001 would result in increased efficacy against gliomas compared with single-agent therapy. In vitro expts. showed that the combination of AEE788 and RAD001 resulted in increased rates of cell cycle arrest and apoptosis and reduced proliferation more than either agent alone. Combined AEE788 and RAD001 given orally to athymic mice bearing established human malignant glioma tumor xenografts resulted in greater tumor growth inhibition and greater increases in median survival than monotherapy. These studies suggest that simultaneous inhibition of growth factor receptor and mTOR pathways offer increased benefit in glioma therapy.

IT **497839-62-0**, AEE 788
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy with inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition)

RN 497839-62-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1060779 HCAPLUS
DOCUMENT NUMBER: 142:38274
TITLE: Preparation of 7H-pyrrolo[2,3-d]pyrimidines as protein tyrosine kinase inhibitors
INVENTOR(S): Bold, Guido; Capraro, Hans-Georg; Caravatti, Giorgio; Traxler, Peter
PATENT ASSIGNEE(S): Switz.
SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U.S. Ser. No. 485,747.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004248911	A1	20041209	US 2004-783000	20040220
WO 2003013541	A1	20030220	WO 2002-EP8780	20020806
WO 2003013541	C1	20040226		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
US 2004242600	A1	20041202	US 2004-485747	20040203
PRIORITY APPLN. INFO.:			GB 2001-19249 A	20010807
			WO 2002-EP8780 W	20020806
			US 2004-485747 A2	20040203

OTHER SOURCE(S): MARPAT 142:38274
GI



I

AB Title compds. [I; R1, R2 = H, (substituted) alkyl, cycloalkyl, heterocyclyl, R4Y(C:Z); R4 = (substituted) amino, heterocyclyl; Y = null, alkyl; Z = O, S, imino; R1R2N = heterocyclyl; R3 = heterocyclyl, (substituted) aryl; G = alkylene, CO, alkylenecarbonyl; Q = NH, CO; X = null, alkylene; with provisos], were prepared Thus, (3-chloro-4-fluorophenyl)-[6-[4-(4-ethylpiperazin-1-ylmethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine (preparation outlined) inhibited the tyrosine kinase activity of HER-1, HER-2, and KDR with IC50 = 0.0031 μM, 0.008 μM, and 0.0107 μM, resp.

IT **497840-89-8P 497841-60-8P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(claimed compound; preparation of pyrrolopyrimidines as protein tyrosine kinase inhibitors)

RN 497840-89-8 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(6-methoxy-3-pyridinyl)-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497841-60-8 HCAPLUS

CN Piperazine, 1-ethyl-4-[4-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]benzoyl]- (9CI) (CA INDEX NAME)



IT 497839-48-2P 497839-49-3P 497839-50-6P
497839-51-7P 497839-52-8P 497839-53-9P
497839-54-0P 497839-55-1P 497839-56-2P
497839-57-3P 497839-58-4P 497839-59-5P
497839-60-8P 497839-61-9P 497839-62-0P
497839-63-1P 497839-64-2P 497839-65-3P
497839-66-4P 497839-67-5P 497839-68-6P
497839-69-7P 497839-70-0P 497839-71-1P
497839-72-2P 497839-73-3P 497839-74-4P
497839-75-5P 497839-76-6P 497839-77-7P
497839-78-8P 497839-79-9P 497839-80-2P
497839-81-3P 497839-82-4P 497839-83-5P
497839-84-6P 497839-85-7P 497839-86-8P
497839-87-9P 497839-88-0P 497839-89-1P
497839-90-4P 497839-91-5P 497839-92-6P
497839-93-7P 497839-94-8P 497839-95-9P
497839-96-0P 497839-97-1P 497839-98-2P
497839-99-3P 497840-00-3P 497840-01-4P
497840-02-5P 497840-04-7P 497840-07-0P
497840-09-2P 497840-11-6P 497840-13-8P
497840-15-0P 497840-17-2P 497840-19-4P
497840-20-7P 497840-22-9P 497840-23-0P
497840-24-1P 497840-25-2P 497840-26-3P
497840-27-4P 497840-28-5P 497840-29-6P
497840-30-9P 497840-31-0P 497840-32-1P
497840-33-2P 497840-34-3P 497840-35-4P
497840-36-5P 497840-37-6P 497840-38-7P
497840-39-8P 497840-40-1P 497840-41-2P
497840-42-3P 497840-43-4P 497840-44-5P
497840-45-6P 497840-46-7P 497840-48-9P
497840-49-0P 497840-50-3P 497840-51-4P
497840-52-5P 497840-53-6P 497840-54-7P
497840-55-8P 497840-56-9P 497840-57-0P
497840-58-1P 497840-59-2P 497840-60-5P
497840-61-6P 497840-62-7P 497840-63-8P
497840-64-9P 497840-65-0P 497840-66-1P
497840-67-2P 497840-68-3P 497840-69-4P
497840-70-7P 497840-71-8P 497840-72-9P
497840-73-0P 497840-74-1P 497840-75-2P
497840-76-3P 497840-77-4P 497840-78-5P
497840-79-6P 497840-80-9P 497840-81-0P
497840-82-1P 497840-83-2P 497840-84-3P
497840-85-4P 497840-86-5P 497840-87-6P

497840-88-7P 497840-90-1P 497840-91-2P
497840-92-3P 497840-93-4P 497840-94-5P
497840-95-6P 497840-96-7P 497840-97-8P
497840-98-9P 497840-99-0P 497841-00-6P
497841-01-7P 497841-02-8P 497841-04-0P
497841-05-1P 497841-06-2P 497841-07-3P
497841-08-4P 497841-09-5P 497841-10-8P
497841-11-9P 497841-12-0P 497841-13-1P
497841-14-2P 497841-15-3P 497841-16-4P
497841-17-5P 497841-18-6P 497841-19-7P
497841-20-0P 497841-21-1P 497841-22-2P
497841-61-9P 497841-62-0P 497841-63-1P
497841-64-2P 497848-06-3P 803706-06-1P
803706-07-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of pyrrolopyrimidines as protein tyrosine kinase inhibitors)

RN 497839-48-2 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-49-3 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-[(diethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-50-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-51-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-52-8 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-53-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-54-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-55-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-[(3,5-dimethyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-56-2 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-[[(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-57-3 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-[[[2-(4-morpholinyl)ethyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-58-4 HCAPLUS
CN 1,2-Ethanediamine, N'-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 497839-59-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-[[(1-methylethyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-60-8 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-61-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(diethylamino)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-62-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-63-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1R)-1-phenylethyl]-6-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-64-2 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-65-3 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1R)-1-phenylethyl]-6-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-66-4 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-(4-morpholinylmethyl)phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-67-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(3,5-dimethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-68-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[[[2-(4-morpholinyl)ethyl]amino]methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-69-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1R)-1-phenylethyl]-6-[4-[[(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-70-0 HCAPLUS
CN 1,2-Ethanediamine, N,N-diethyl-N'-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-71-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[[(1,1-dimethylethyl)amino]methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-72-2 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(ethylamino)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-73-3 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(methylamino)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-74-4 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-

[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-75-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-76-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[4-(phenylmethoxy)phenyl]-6-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-77-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-(4-morpholinylmethyl)phenyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-78-8 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(diethylamino)methyl]phenyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-79-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-80-2 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[4-(phenylmethoxy)phenyl]-6-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-81-3 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(3,5-dimethyl-1-piperazinyl)methyl]phenyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-82-4 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[3-[(dimethylamino)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-83-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[3-[(diethylamino)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-84-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[3-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-85-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1R)-1-phenylethyl]-6-[3-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-86-8 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[3-[(4-methyl-1-

piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-87-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1R)-1-phenylethyl]-6-[3-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-88-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[3-(4-morpholinylmethyl)phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-89-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[3-[(3,5-dimethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-90-4 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[3-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-91-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[3-[(diethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-92-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[3-[(4-ethyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-93-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[3-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-94-8 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[3-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-95-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[3-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-96-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[3-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-97-1 HCAPLUS
CN 1-Piperidineacetamide, N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-98-2 HCAPLUS
CN 1-Pyrrolidineacetamide, N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-99-3 HCAPLUS
CN 4-Morpholineacetamide, N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-00-3 HCAPLUS
CN 1-Piperazineacetamide, 4-methyl-N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-01-4 HCAPLUS
CN Acetamide, 2-(dimethylamino)-N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-02-5 HCAPLUS
CN 1-Piperazineacetamide, 4-ethyl-N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-04-7 HCAPLUS
CN Acetamide, N-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 497840-07-0 HCAPLUS
CN 1-Piperazineacetamide, N-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]-4-ethyl- (9CI) (CA INDEX NAME)



RN 497840-09-2 HCAPLUS
CN 4-Morpholineacetamide, N-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 497840-11-6 HCAPLUS
CN 1-Piperidineacetamide, N-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 497840-13-8 HCAPLUS
CN 1-Piperazineacetamide, N-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 497840-15-0 HCAPLUS
CN Acetamide, 2-(dimethylamino)-N-[[4-[4-[[4-(phenylmethoxy)phenyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 497840-17-2 HCAPLUS
CN 1-Piperazineacetamide, 4-methyl-N-[[4-[4-[[4-(phenylmethoxy)phenyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 497840-19-4 HCAPLUS
CN 1-Piperidineacetamide, N-[[4-[4-[[4-(phenylmethoxy)phenyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 497840-20-7 HCAPLUS
CN 1-Piperidinepropanamide, N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-22-9 HCAPLUS
CN Propanamide, 3-(diethylamino)-N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-23-0 HCAPLUS
CN Butanamide, 4-(dimethylamino)-N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-24-1 HCAPLUS
CN 2-Pyridinecarboxamide, N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-25-2 HCAPLUS
CN Propanamide, N-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]-3-(diethylamino)- (9CI) (CA INDEX NAME)



RN 497840-26-3 HCAPLUS
CN 2-Pyridinecarboxamide, N-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 497840-27-4 HCAPLUS
CN Butanamide, N-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 497840-28-5 HCAPLUS
CN 1-Piperidinepropanamide, N-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 497840-29-6 HCAPLUS
CN Acetamide, 2-(dimethylamino)-N-[[3-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-30-9 HCAPLUS
CN 1-Piperazineacetamide, 4-methyl-N-[[3-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-31-0 HCAPLUS
CN Acetamide, N-[[3-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 497840-32-1 HCAPLUS
CN 1-Piperazineacetamide, N-[[3-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 497840-33-2 HCAPLUS
CN 1-Piperidineacetamide, N-[[3-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 497840-34-3 HCAPLUS
CN Phenol, 2-methyl-5-[[6-[3-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-35-4 HCAPLUS
CN Phenol, 5-[[6-[3-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 497840-36-5 HCAPLUS

CN Phenol, 2-methoxy-5-[[6-[3-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-37-6 HCAPLUS
CN Phenol, 5-[[6-[3-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-2-methoxy- (9CI) (CA INDEX NAME)



RN 497840-38-7 HCAPLUS
CN Phenol, 5-[[6-[4-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 497840-39-8 HCAPLUS
CN Phenol, 2-methyl-5-[[6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-40-1 HCAPLUS
CN Phenol, 5-[[6-[4-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-2-methoxy- (9CI) (CA INDEX NAME)



RN 497840-41-2 HCAPLUS
CN Phenol, 2-methoxy-5-[[6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-42-3 HCAPLUS
CN Phenol, 2-methoxy-5-[[6-[4-(4-morpholinylmethyl)phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-43-4 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1R)-1-(4-chlorophenyl)ethyl]-6-[4-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-44-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1R)-1-(4-chlorophenyl)ethyl]-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-45-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1R)-1-(4-chlorophenyl)ethyl]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-46-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chlorophenyl)-6-[4-[(dimethylamino)methyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 497840-48-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chlorophenyl)-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 497840-49-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chlorophenyl)-6-[4-(4-morpholinylmethyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 497840-50-3 HCAPLUS
CN Ethanol, 2,2'-[[[4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]imino]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-51-4 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-chlorophenyl)methyl]-6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-52-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-chlorophenyl)methyl]-6-[4-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-53-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-chlorophenyl)methyl]-6-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-54-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-chlorophenyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-55-8 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-chlorophenyl)methyl]-6-[4-[(diethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-56-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-chlorophenyl)methyl]-6-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-57-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-chlorophenyl)methyl]-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-58-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2-chlorophenyl)methyl]-6-[4-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-59-2 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2-chlorophenyl)methyl]-6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-60-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2-chlorophenyl)methyl]-6-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-61-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2-chlorophenyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-62-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2-chlorophenyl)methyl]-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-63-8 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2-chlorophenyl)methyl]-6-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-64-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2,5-dichlorophenyl)methyl]-6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-65-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2,5-dichlorophenyl)methyl]-6-[4-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-66-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2,5-dichlorophenyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-67-2 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2,5-dichlorophenyl)methyl]-6-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-68-3 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2,5-dichlorophenyl)methyl]-6-[4-[(diethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)

RN 497840-71-8 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 497840-72-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(diethylamino)methyl]phenyl]-N-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 497840-73-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-methoxyphenyl)methyl]-6-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-69-4 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2,5-dichlorophenyl)methyl]-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-70-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2,5-dichlorophenyl)methyl]-6-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)





RN 497840-74-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-methoxyphenyl)methyl]-6-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-75-2 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-methoxyphenyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-76-3 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-methoxyphenyl)methyl]-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-77-4 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 497840-78-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-methylphenyl)methyl]-6-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-79-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-methylphenyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-80-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 497840-81-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(diethylamino)methyl]phenyl]-N-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 497840-82-1 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-methylphenyl)methyl]-6-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-83-2 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-methylphenyl)methyl]-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-84-3 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 497840-85-4 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1,3-benzodioxol-5-yl-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-86-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1,3-benzodioxol-5-yl-6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-87-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1,3-benzodioxol-5-yl-6-[4-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-88-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1,3-benzodioxol-5-yl-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-90-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(6-methoxy-3-pyridinyl)-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-91-2 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 497840-92-3 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 497840-93-4 HCAPLUS
CN 2(1H)-Pyridinone, 5-[[6-[4-(4-morpholinylmethyl)phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-94-5 HCAPLUS
CN 2(1H)-Pyridinone, 5-[[6-[4-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-95-6 HCAPLUS
CN 2(1H)-Pyridinone, 5-[[6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-96-7 HCAPLUS
CN 2(1H)-Pyridinone, 5-[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-97-8 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(6-methoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 497840-98-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(6-methoxy-3-pyridinyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-99-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-[(6-methoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 497841-00-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(2-methoxy-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 497841-01-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2-methoxy-4-pyridinyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497841-02-8 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-[(2-methoxy-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 497841-04-0 HCAPLUS
CN 2(1H)-Pyridinone, 5-[[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 497841-05-1 HCAPLUS
CN 2(1H)-Pyridinone, 5-[[[6-[4-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 497841-06-2 HCAPLUS
CN 2(1H)-Pyridinone, 5-[[[6-[4-(4-morpholinylmethyl)phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 497841-07-3 HCAPLUS
CN 2(1H)-Pyridinone, 4-[[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 497841-08-4 HCAPLUS
CN 2(1H)-Pyridinone, 4-[[[6-[4-(4-morpholinylmethyl)phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 497841-09-5 HCAPLUS
CN 2(1H)-Pyridinone, 4-[[[6-[4-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 497841-10-8 HCAPLUS
CN 2(1H)-Pyridinone, 4-[[[6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 497841-11-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(2-methoxy-4-pyridinyl)-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497841-12-0 HCAPLUS
CN 2(1H)-Pyridinone, 4-[[6-[4-(4-morpholinylmethyl)phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497841-13-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(2-methoxy-4-pyridinyl)-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497841-14-2 HCAPLUS
CN 2(1H)-Pyridinone, 4-[[6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497841-15-3 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-(2-methoxy-4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 497841-16-4 HCAPLUS
CN 2(1H)-Pyridinone, 4-[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497841-17-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-(2-methoxy-4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 497841-18-6 HCAPLUS
CN 2(1H)-Pyridinone, 4-[[6-[4-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497841-19-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]- (9CI) (CA INDEX NAME)



RN 497841-20-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497841-21-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497841-22-2 HCAPLUS
CN Benzenemethanamine, 4-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 497841-61-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[[(1-methylethyl)amino]methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497841-62-0 HCAPLUS
CN Piperazine, 1-[4-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]benzoyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 497841-63-1 HCAPLUS
CN Morpholine, 4-[4-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]benzoyl]- (9CI) (CA INDEX NAME)



RN 497841-64-2 HCAPLUS
CN Benzamide, 4-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 497848-06-3 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2-chlorophenyl)methyl]-6-[4-[(diethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 803706-06-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(1-phenylethyl)-6-[4-(1-piperazinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 803706-07-2 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1R)-1-phenylethyl]-6-[4-(1-piperazinylmethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **497841-41-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolopyrimidines as protein tyrosine kinase inhibitors)
RN 497841-41-5 HCAPLUS
CN 2-Propenamide, N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **187724-58-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrrolopyrimidines as protein tyrosine kinase inhibitors)
RN 187724-58-9 HCAPLUS
CN Benzamide, 4-[4-[(3-chlorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



IT **497841-36-8P 497841-37-9P 497841-38-0P**
497841-39-1P 497841-40-4P 497841-42-6P
497841-43-7P 497841-44-8P 803706-08-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolopyrimidines as protein tyrosine kinase inhibitors)
RN 497841-36-8 HCAPLUS
CN Benzonitrile, 4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497841-37-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-(aminomethyl)phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497841-38-0 HCAPLUS
CN Acetamide, 2-chloro-N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497841-39-1 HCAPLUS
CN Acetamide, 2-chloro-N-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 497841-40-4 HCAPLUS

CN Acetamide, 2-chloro-N-[[4-[4-[[4-(phenylmethoxy)phenyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 497841-42-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-(aminomethyl)phenyl]-N-(3-chloro-4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 497841-43-7 HCAPLUS
CN Acetamide, 2-chloro-N-[[3-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497841-44-8 HCAPLUS
CN Acetamide, 2-chloro-N-[[3-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 803706-08-3 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 18 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:913614 HCAPLUS
DOCUMENT NUMBER: 142:403
TITLE: Tumor Cell and Endothelial Cell Therapy of Oral Cancer by Dual Tyrosine Kinase Receptor Blockade
AUTHOR(S): Yigitbasi, Orhan G.; Younes, Maher N.; Doan, Dao; Jasser, Samar A.; Schiff, Bradley A.; Bucana, Corazon D.; Bekele, Benjamin N.; Fidler, Isaiah J.; Myers, Jeffrey N.
CORPORATE SOURCE: Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030-4009, USA
SOURCE: Cancer Research (2004), 64(21), 7977-7984
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal

LANGUAGE: English

AB Expression of the epidermal growth factor (EGF) and activation of its receptor (EGFR), a tyrosine kinase, are associated with progressive growth of head and neck cancer. Expression of the vascular endothelial growth factor (VEGF) is associated with angiogenesis and progressive growth of tumor. The tyrosine kinase inhibitor NVP-AEE788 (AEE788) blocks the EGF and VEGF signaling pathways. We examined the effects of AEE788 administered alone, or with paclitaxel (Taxol), on the progression of human head and neck cancer implanted orthotopically into nude mice. Cells of two different human oral cancer lines, JMAR and MDA1986, were injected into the tongues of nude mice. Mice with established tumors were randomized to receive three times per wk oral AEE788, once weekly injected paclitaxel, AEE788 plus paclitaxel, or placebo. Oral tumors were resected at necropsy. Kinase activity, cell proliferation, apoptosis, and mean vessel d. were determined by immunohistochem. immunofluorescent staining. AEE788 inhibited cell growth, induced apoptosis, and reduced the phosphorylation of EGFR, VEGFR-2, AKT, and mitogen-activated protein kinase in both cell lines. Mice treated with AEE788 and AEE788 plus paclitaxel had decreased microvessel d., decreased proliferative index, and increased apoptosis. Hence, AEE788 inhibited tumor vascularization and growth and prolonged survival. Inhibition of EGFR and VEGFR phosphorylation by AEE788 effectively inhibits cellular proliferation of squamous cell carcinoma of the head and neck, induces apoptosis of tumor endothelial cells and tumor cells, and is well tolerated in mice. These data recommend the consideration of patients with head and neck cancer for inclusion in clin. trials of AEE788.

IT **497839-62-0**, AEE 788
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade)

RN 497839-62-0 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:567549 HCAPLUS

DOCUMENT NUMBER: 141:253894

TITLE: AEE788: A Dual Family Epidermal Growth Factor

Receptor/ErbB2 and Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor with Antitumor and Antiangiogenic Activity

AUTHOR(S): Traxler, Peter; Allegrini, Peter R.; Brandt, Ralf; Brueggen, Josef; Cozens, Robert; Fabbro, Doriano; Grosios, Konstantina; Lane, Heidi A.; McSheehy, Paul; Mestan, Juergen; Meyer, Thomas; Tang, Careen; Wartmann, Markus; Wood, Jeanette; Caravatti, Giorgio

CORPORATE SOURCE: Novartis Institutes for Biomedical Research, Oncology Research, Basel, Switz.

SOURCE: Cancer Research (2004), 64(14), 4931-4941
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Aberrant epidermal growth factor receptor (EGFR) and ErbB2 expression are associated with advanced disease and poor patient prognosis in many tumor types (breast, lung, ovarian, prostate, glioma, gastric, and squamous carcinoma of head and neck). In addition, a constitutively active EGFR type III deletion mutant has been identified in non-small cell lung cancer, glioblastomas, and breast tumors. Hence, members of the EGFR family are viewed as promising therapeutic targets in the fight against cancer. In a similar vein, vascular endothelial growth factor (VEGF) receptor kinases are also promising targets in terms of an antiangiogenic treatment strategy. AEE788, obtained by optimization of the 7H-pyrrolo[2,3-d]pyrimidine lead scaffold, is a potent combined inhibitor of both epidermal growth factor (EGF) and VEGF receptor tyrosine kinase family members on the isolated enzyme level and in cellular systems. At the enzyme level, AEE788 inhibited EGFR and VEGF receptor tyrosine kinases in the nM range (IC50s: EGFR 2 nM, ErbB2 6 nM, KDR 77 nM, and Flt-1 59 nM). In cells, growth factor-induced EGFR and ErbB2 phosphorylation was also efficiently inhibited (IC50s: 11 and 220 nM, resp.). AEE788 demonstrated antiproliferative activity against a range of EGFR and ErbB2-overexpressing cell lines (including EGFRvIII-dependent lines) and inhibited the proliferation of epidermal growth factor- and VEGF-stimulated human umbilical vein endothelial cells. These properties, combined with a favorable pharmacokinetic profile, were associated with a potent antitumor activity in a number of animal models of cancer, including tumors that overexpress EGFR and or ErbB2. Oral administration of AEE788 to tumor-bearing mice resulted in high and persistent compound levels in tumor tissue. Moreover, AEE788 efficiently inhibited growth factor-induced EGFR and ErbB2 phosphorylation in tumors for >72 h, a phenomenon correlating with the antitumor efficacy of intermittent treatment schedules. Strikingly, AEE788 also inhibited VEGF-induced angiogenesis in a murine implant model. Antiangiogenic activity was also apparent by measurement of tumor vascular permeability and interstitial leakage space using dynamic contrast enhanced magnetic resonance imaging methodol. Taken together, these data indicate that AEE788 has potential as an anticancer agent targeting deregulated tumor cell proliferation as well as angiogenic parameters. Consequently, AEE788 is currently in Phase I clin. trials in oncol.

IT 497839-62-0, AEE 788

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(EGFR/ErbB2 and VEGFR tyrosine kinase inhibitor AEE788 with antitumor and antiangiogenic activity)

RN 497839-62-0 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-

piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:356449 HCAPLUS
DOCUMENT NUMBER: 138:368905
TITLE: Preparation of 7H-pyrrolo[2,3-d]pyrimidine derivatives for treatment of solid tumor diseases
INVENTOR(S): Ball, Howard Ashley; Cohen, Pamela Sarah; Lee, Lucy; Ravera, Christina Portrude
PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma Gmbh
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003037897	A2	20030508	WO 2002-EP12024		20021028
WO 2003037897	A3	20030918			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW					
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR					
EP 1441736	A2	20040804	EP 2002-781294		20021028
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
JP 2005507424	T2	20050317	JP 2003-540178		20021028
US 2005038048	A1	20050217	US 2004-493787		20040426
PRIORITY APPLN. INFO.:			US 2001-340923P	P	20011029
			US 2002-361655P	P	20020305
			US 2002-379365P	P	20020509
			WO 2002-EP12024	W	20021028

OTHER SOURCE(S): MARPAT 138:368905
GI



I



II

AB Title compds. I [wherein R1 and R2 = independently H or (un)substituted (cyclo)alkyl, heterocyclyl, or R4YCZ, with the proviso that R1 and R2 ≠ both H; or NR1R2 = heterocyclyl; R3 = heterocyclyl or (un)substituted aryl; R4 = (un)substituted amino or heterocyclyl; G = alkylene, CO, or alkylene-CO; Q = NH or O, with the proviso Q = O if G = CO or alkylene-CO; X = absent or alkylene, with the proviso R3 = heterocyclyl if X is absent; Y = absent or alkyl; Z = O, S, or NH; or pharmaceutically acceptable salts thereof] were prepared as anticancer agents. For example, substitution of 4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)benzoic acid Et ester with (R)-phenethylamine in BuOH gave the benzenamine. Reduction of the ester using lithium aluminum hydride, followed by reaction with thionyl chloride in toluene afforded the chloromethyl derivative Coupling with N-methylpiperazine in the presence of K2CO3 in DMF yielded II. Thus, I are useful for the treatment of patients suffering from a solid tumor disease selected from carcinoma of the bladder, renal carcinoma, squamous cell carcinoma of the skin, head and neck cancer, especially squamous cell head and neck cancer, lung cancer, especially non small cell lung cancer (NSCLC), tumors of the gastrointestinal tract, glioma, and mesothelioma or metastases of such solid tumor diseases (no data). Also disclosed is a method of administering the title 7H-pyrrolo[2,3-d]pyrimidines over at least a three week time period on only about 40% to about 71% of the days in the time period (no data).

IT **497839-60-8P**, [6-[4-[(4-Methylpiperazin-1-yl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]((R)-1-phenylethyl)amine **497839-61-9P**, [6-[4-[(Diethylamino)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-1-phenylethyl)amine **497839-62-0P**, [6-[4-[(4-Ethylpiperazin-1-yl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-1-phenylethyl)amine **497839-63-1P**, ((R)-1-Phenylethyl)[6-[4-

(pyrrolidin-1-ylmethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine **497839-64-2P**, [6-(4-Dimethylaminomethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-1-phenylethyl)amine **497839-65-3P**, ((R)-1-Phenylethyl)[6-[4-(piperidin-1-ylmethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine **497839-66-4P**, [6-[4-(Morpholin-4-ylmethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-1-phenylethyl)amine **497839-67-5P**, [6-[4-[(3,5-Dimethylpiperazin-1-yl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]((R)-1-phenylethyl)amine **497839-68-6P**, [6-[4-[[[2-(Morpholin-4-yl)ethyl]amino]methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]((R)-1-phenylethyl)amine **497839-69-7P**, ((R)-1-Phenylethyl)[6-[4-[(tetrahydropyran-4-ylamino)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antitumor agent; preparation of pyrrolopyrimidines for treatment of solid tumor diseases)

RN 497839-60-8 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-61-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(diethylamino)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-62-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-63-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1R)-1-phenylethyl]-6-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-64-2 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-65-3 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1R)-1-phenylethyl]-6-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-66-4 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-(4-morpholinylmethyl)phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-67-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(3,5-dimethyl-1-

piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-68-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[[[2-(4-morpholinyl)ethyl]amino]methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-69-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1R)-1-phenylethyl]-6-[4-[[(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 21 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:133054 HCAPLUS
DOCUMENT NUMBER: 138:170253
TITLE: Preparation of 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidines as protein tyrosine kinase inhibitors
INVENTOR(S): Bold, Guido; Capraro, Hans-Georg; Caravatti, Giorgio; Traxler, Peter
PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003013541	A1	20030220	WO 2002-EP8780		20020806
WO 2003013541	C1	20040226			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW					
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR					
CA 2453881	AA	20030220	CA 2002-2453881		20020806
EP 1416935	A1	20040512	EP 2002-758437		20020806
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
BR 2002011801	A	20040831	BR 2002-11801		20020806
CN 1538847	A	20041020	CN 2002-815351		20020806
JP 2005501077	T2	20050113	JP 2003-518550		20020806
NZ 530824	A	20050826	NZ 2002-530824		20020806
ZA 2004000271	A	20041101	ZA 2004-271		20040114
US 2004242600	A1	20041202	US 2004-485747		20040203
NO 2004000540	A	20040205	NO 2004-540		20040205
US 2004248911	A1	20041209	US 2004-783000		20040220
PRIORITY APPLN. INFO.:			GB 2001-19249	A	20010807
			WO 2002-EP8780	W	20020806

US 2004-485747 A2 20040203

OTHER SOURCE(S): MARPAT 138:170253

GI



I



II

AB The title compds. I [R1, R2 = H, alkyl, cycloalkyl, etc.; or NR1R2 = heterocyclyl; R3 = heterocyclyl, (un)substituted aryl; G = alkylene, CO, alkyleneCO wherein the carbonyl group is attached to the NR1R2; Q = NH, O, with the proviso that Q = O if G = CO or alkyleneCO; X is either not present or alkylene, with the proviso that a heterocyclic radical R3 is bonded via a ring carbon if X is not present] and their salts, useful for treatment of a disease which responds to an inhibition of a protein tyrosine kinase, especially for the treatment of a proliferative disease, such as a tumor, were prepared and formulated. E.g., a 4-step synthesis of II, starting from Et 4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)benzoate and 3-chloro-4-fluoroaniline, was given. Compds. I were tested for their inhibition of the tyrosine kinase activity of EGF-R (HER-1), ErbB-2 (HER-2) and VEGF receptor (KDR) (data given for 21 exemplified compds.).

IT **497840-89-8P 497841-60-8P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidines as protein tyrosine kinase inhibitors)

RN 497840-89-8 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(6-methoxy-3-pyridinyl)-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497841-60-8 HCAPLUS
CN Piperazine, 1-ethyl-4-[4-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]benzoyl]- (9CI) (CA INDEX NAME)



IT 497839-48-2P 497839-49-3P 497839-50-6P
497839-51-7P 497839-52-8P 497839-53-9P
497839-54-0P 497839-55-1P 497839-56-2P
497839-57-3P 497839-58-4P 497839-59-5P
497839-60-8P 497839-61-9P 497839-62-0P
497839-63-1P 497839-64-2P 497839-65-3P
497839-66-4P 497839-67-5P 497839-68-6P
497839-69-7P 497839-70-0P 497839-71-1P
497839-72-2P 497839-73-3P 497839-74-4P
497839-75-5P 497839-76-6P 497839-77-7P
497839-78-8P 497839-79-9P 497839-80-2P
497839-81-3P 497839-82-4P 497839-83-5P
497839-84-6P 497839-85-7P 497839-86-8P
497839-87-9P 497839-88-0P 497839-89-1P
497839-90-4P 497839-91-5P 497839-92-6P
497839-93-7P 497839-94-8P 497839-95-9P
497839-96-0P 497839-97-1P 497839-98-2P
497839-99-3P 497840-00-3P 497840-01-4P
497840-02-5P 497840-04-7P 497840-07-0P
497840-09-2P 497840-11-6P 497840-13-8P

497840-15-0P 497840-17-2P 497840-19-4P
497840-20-7P 497840-22-9P 497840-23-0P
497840-24-1P 497840-25-2P 497840-26-3P
497840-27-4P 497840-28-5P 497840-29-6P
497840-30-9P 497840-31-0P 497840-32-1P
497840-33-2P 497840-34-3P 497840-35-4P
497840-36-5P 497840-37-6P 497840-38-7P
497840-39-8P 497840-40-1P 497840-41-2P
497840-42-3P 497840-43-4P 497840-44-5P
497840-45-6P 497840-46-7P 497840-47-8P
497840-48-9P 497840-49-0P 497840-50-3P
497840-51-4P 497840-52-5P 497840-53-6P
497840-54-7P 497840-55-8P 497840-56-9P
497840-57-0P 497840-58-1P 497840-59-2P
497840-60-5P 497840-61-6P 497840-62-7P
497840-63-8P 497840-64-9P 497840-65-0P
497840-66-1P 497840-67-2P 497840-68-3P
497840-69-4P 497840-70-7P 497840-71-8P
497840-72-9P 497840-73-0P 497840-74-1P
497840-75-2P 497840-76-3P 497840-77-4P
497840-78-5P 497840-79-6P 497840-80-9P
497840-81-0P 497840-82-1P 497840-83-2P
497840-84-3P 497840-85-4P 497840-86-5P
497840-87-6P 497840-88-7P 497840-90-1P
497840-91-2P 497840-92-3P 497840-93-4P
497840-94-5P 497840-95-6P 497840-96-7P
497840-97-8P 497840-98-9P 497840-99-0P
497841-00-6P 497841-01-7P 497841-02-8P
497841-03-9P 497841-04-0P 497841-05-1P
497841-06-2P 497841-07-3P 497841-08-4P
497841-09-5P 497841-10-8P 497841-11-9P
497841-12-0P 497841-13-1P 497841-14-2P
497841-15-3P 497841-16-4P 497841-17-5P
497841-18-6P 497841-19-7P 497841-20-0P
497841-21-1P 497841-22-2P 497841-61-9P
497841-62-0P 497841-63-1P 497841-64-2P
497848-06-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidines as protein tyrosine kinase inhibitors)

RN 497839-48-2 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-49-3 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-[(diethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-50-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-51-7 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-52-8 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-53-9 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-54-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-55-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-[(3,5-dimethyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-56-2 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-[[(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-57-3 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-[[[2-(4-morpholinyl)ethyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-58-4 HCAPLUS
CN 1,2-Ethanediamine, N'-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 497839-59-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[4-[[(1-methylethyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-60-8 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-61-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(diethylamino)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-62-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-63-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1R)-1-phenylethyl]-6-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-64-2 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-65-3 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1R)-1-phenylethyl]-6-[4-(1-

piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-66-4 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-(4-morpholinylmethyl)phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-67-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(3,5-dimethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-68-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[[[2-(4-morpholinyl)ethyl]amino]methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-69-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1R)-1-phenylethyl]-6-[4-[[(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-70-0 HCAPLUS
CN 1,2-Ethanediamine, N,N-diethyl-N'-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-71-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[[(1,1-dimethylethyl)amino]methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-72-2 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(ethylamino)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-73-3 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(methylamino)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-74-4 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-75-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-76-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[4-(phenylmethoxy)phenyl]-6-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-77-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-(4-morpholinylmethyl)phenyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-78-8 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(diethylamino)methyl]phenyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-79-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-80-2 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[4-(phenylmethoxy)phenyl]-6-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-81-3 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(3,5-dimethyl-1-piperazinyl)methyl]phenyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-82-4 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[3-[(dimethylamino)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-83-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[3-[(diethylamino)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-84-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[3-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-85-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1R)-1-phenylethyl]-6-[3-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-86-8 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[3-[(4-methyl-1-

piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-87-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1R)-1-phenylethyl]-6-[3-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-88-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[3-(4-morpholinylmethyl)phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-89-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[3-[(3,5-dimethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-90-4 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[3-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-91-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[3-[(diethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-92-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[3-[(4-ethyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-93-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[3-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-94-8 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[3-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497839-95-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[3-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-96-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-6-[3-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497839-97-1 HCAPLUS
CN 1-Piperidineacetamide, N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-98-2 HCAPLUS
CN 1-Pyrrolidineacetamide, N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497839-99-3 HCAPLUS
CN 4-Morpholineacetamide, N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-00-3 HCAPLUS
CN 1-Piperazineacetamide, 4-methyl-N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-01-4 HCAPLUS
CN Acetamide, 2-(dimethylamino)-N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-02-5 HCAPLUS
CN 1-Piperazineacetamide, 4-ethyl-N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-04-7 HCAPLUS
CN Acetamide, N-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 497840-07-0 HCAPLUS
CN 1-Piperazineacetamide, N-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]-4-ethyl- (9CI) (CA INDEX NAME)



RN 497840-09-2 HCAPLUS
CN 4-Morpholineacetamide, N-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 497840-11-6 HCAPLUS
CN 1-Piperidineacetamide, N-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 497840-13-8 HCAPLUS
CN 1-Piperazineacetamide, N-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 497840-15-0 HCAPLUS
CN Acetamide, 2-(dimethylamino)-N-[[4-[4-[[4-(phenylmethoxy)phenyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 497840-17-2 HCAPLUS
CN 1-Piperazineacetamide, 4-methyl-N-[[4-[4-[[4-(phenylmethoxy)phenyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 497840-19-4 HCAPLUS
CN 1-Piperidineacetamide, N-[[4-[4-[[4-(phenylmethoxy)phenyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 497840-20-7 HCAPLUS
CN 1-Piperidinepropanamide, N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-22-9 HCAPLUS
CN Propanamide, 3-(diethylamino)-N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-23-0 HCAPLUS
CN Butanamide, 4-(dimethylamino)-N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-24-1 HCAPLUS
CN 2-Pyridinecarboxamide, N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-25-2 HCAPLUS
CN Propanamide, N-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]-3-(diethylamino)- (9CI) (CA INDEX NAME)



RN 497840-26-3 HCAPLUS
CN 2-Pyridinecarboxamide, N-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 497840-27-4 HCAPLUS
CN Butanamide, N-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 497840-28-5 HCAPLUS
CN 1-Piperidinepropanamide, N-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 497840-29-6 HCAPLUS
CN Acetamide, 2-(dimethylamino)-N-[[3-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-30-9 HCAPLUS
CN 1-Piperazineacetamide, 4-methyl-N-[[3-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-31-0 HCAPLUS
CN Acetamide, N-[[3-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 497840-32-1 HCAPLUS
CN 1-Piperazineacetamide, N-[[3-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 497840-33-2 HCAPLUS
CN 1-Piperidineacetamide, N-[[3-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 497840-34-3 HCAPLUS
CN Phenol, 2-methyl-5-[[6-[3-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-35-4 HCAPLUS
CN Phenol, 5-[[6-[3-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 497840-36-5 HCAPLUS

CN Phenol, 2-methoxy-5-[[6-[3-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-37-6 HCAPLUS
CN Phenol, 5-[[6-[3-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-2-methoxy- (9CI) (CA INDEX NAME)



RN 497840-38-7 HCAPLUS
CN Phenol, 5-[[6-[4-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 497840-39-8 HCAPLUS
CN Phenol, 2-methyl-5-[[6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-40-1 HCAPLUS
CN Phenol, 5-[[6-[4-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-2-methoxy- (9CI) (CA INDEX NAME)



RN 497840-41-2 HCAPLUS
CN Phenol, 2-methoxy-5-[[6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-42-3 HCAPLUS
CN Phenol, 2-methoxy-5-[[6-[4-(4-morpholinylmethyl)phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-43-4 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1R)-1-(4-chlorophenyl)ethyl]-6-[4-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-44-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1R)-1-(4-chlorophenyl)ethyl]-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-45-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1R)-1-(4-chlorophenyl)ethyl]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-46-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chlorophenyl)-6-[4-[(dimethylamino)methyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 497840-47-8 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chlorophenyl)-6-[4-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-48-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chlorophenyl)-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 497840-49-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chlorophenyl)-6-[4-(4-morpholinylmethyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 497840-50-3 HCAPLUS
CN Ethanol, 2,2'-[[[4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]imino]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497840-51-4 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-chlorophenyl)methyl]-6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-52-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-chlorophenyl)methyl]-6-[4-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-53-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-chlorophenyl)methyl]-6-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-54-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-chlorophenyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-55-8 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-chlorophenyl)methyl]-6-[4-[(diethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-56-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-chlorophenyl)methyl]-6-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-57-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-chlorophenyl)methyl]-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-58-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2-chlorophenyl)methyl]-6-[4-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-59-2 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2-chlorophenyl)methyl]-6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-60-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2-chlorophenyl)methyl]-6-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-61-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2-chlorophenyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-62-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2-chlorophenyl)methyl]-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-63-8 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2-chlorophenyl)methyl]-6-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-64-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2,5-dichlorophenyl)methyl]-6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-65-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2,5-dichlorophenyl)methyl]-6-[4-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-66-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2,5-dichlorophenyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-67-2 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2,5-dichlorophenyl)methyl]-6-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-68-3 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2,5-dichlorophenyl)methyl]-6-[4-[(diethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-69-4 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2,5-dichlorophenyl)methyl]-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-70-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2,5-dichlorophenyl)methyl]-6-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-71-8 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 497840-72-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(diethylamino)methyl]phenyl]-N-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 497840-73-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-methoxyphenyl)methyl]-6-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-74-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-methoxyphenyl)methyl]-6-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-75-2 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-methoxyphenyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-76-3 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-methoxyphenyl)methyl]-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-77-4 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 497840-78-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-methylphenyl)methyl]-6-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-79-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-methylphenyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-80-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 497840-81-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(diethylamino)methyl]phenyl]-N-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 497840-82-1 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-methylphenyl)methyl]-6-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-83-2 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(3-methylphenyl)methyl]-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-84-3 HCAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 497840-85-4 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1,3-benzodioxol-5-yl-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-86-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1,3-benzodioxol-5-yl-6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-87-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1,3-benzodioxol-5-yl-6-[4-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-88-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1,3-benzodioxol-5-yl-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-90-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(6-methoxy-3-pyridinyl)-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-91-2 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 497840-92-3 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 497840-93-4 HCAPLUS
CN 2(1H)-Pyridinone, 5-[[6-[4-(4-morpholinylmethyl)phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-94-5 HCAPLUS
CN 2(1H)-Pyridinone, 5-[[6-[4-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-95-6 HCAPLUS
CN 2(1H)-Pyridinone, 5-[[6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-96-7 HCAPLUS
CN 2(1H)-Pyridinone, 5-[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-97-8 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(6-methoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 497840-98-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(6-methoxy-3-pyridinyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-99-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-[(6-methoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 497841-00-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(2-methoxy-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 497841-01-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2-methoxy-4-pyridinyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497841-02-8 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-[(2-methoxy-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 497841-03-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2-methoxy-4-pyridinyl)methyl]-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497841-04-0 HCAPLUS
CN 2(1H)-Pyridinone, 5-[[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 497841-05-1 HCAPLUS
CN 2(1H)-Pyridinone, 5-[[[6-[4-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 497841-06-2 HCAPLUS
CN 2(1H)-Pyridinone, 5-[[[6-[4-(4-morpholinylmethyl)phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 497841-07-3 HCAPLUS
CN 2(1H)-Pyridinone, 4-[[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 497841-08-4 HCAPLUS
CN 2(1H)-Pyridinone, 4-[[[6-[4-(4-morpholinylmethyl)phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 497841-09-5 HCAPLUS
CN 2(1H)-Pyridinone, 4-[[[6-[4-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 497841-10-8 HCAPLUS
CN 2(1H)-Pyridinone, 4-[[[6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 497841-11-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(2-methoxy-4-pyridinyl)-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497841-12-0 HCAPLUS
CN 2(1H)-Pyridinone, 4-[[6-[4-(4-morpholinylmethyl)phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497841-13-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(2-methoxy-4-pyridinyl)-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497841-14-2 HCAPLUS
CN 2(1H)-Pyridinone, 4-[[6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497841-15-3 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-(2-methoxy-4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 497841-16-4 HCAPLUS
CN 2(1H)-Pyridinone, 4-[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497841-17-5 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-(2-methoxy-4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 497841-18-6 HCAPLUS
CN 2(1H)-Pyridinone, 4-[[6-[4-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-

d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497841-19-7 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]- (9CI) (CA INDEX NAME)



RN 497841-20-0 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497841-21-1 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497841-22-2 HCAPLUS
CN Benzenemethanamine, 4-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 497841-61-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[[(1-methylethyl)amino]methyl]phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497841-62-0 HCAPLUS
CN Piperazine, 1-[4-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]benzoyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 497841-63-1 HCAPLUS
CN Morpholine, 4-[4-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]benzoyl]- (9CI) (CA INDEX NAME)



RN 497841-64-2 HCAPLUS
CN Benzamide, 4-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 497848-06-3 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2-chlorophenyl)methyl]-6-[4-[(diethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



IT **187724-58-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidines as protein tyrosine kinase inhibitors)
RN 187724-58-9 HCAPLUS
CN Benzamide, 4-[4-[(3-chlorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



IT **497841-36-8P 497841-37-9P 497841-38-0P**
497841-39-1P 497841-40-4P 497841-42-6P
497841-43-7P 497841-44-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidines as protein tyrosine kinase inhibitors)
RN 497841-36-8 HCAPLUS
CN Benzonitrile, 4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497841-37-9 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-(aminomethyl)phenyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497841-38-0 HCAPLUS
CN Acetamide, 2-chloro-N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497841-39-1 HCAPLUS
CN Acetamide, 2-chloro-N-[[4-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 497841-40-4 HCAPLUS
CN Acetamide, 2-chloro-N-[[4-[4-[[4-(phenylmethoxy)phenyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 497841-42-6 HCAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-(aminomethyl)phenyl]-N-(3-chloro-4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 497841-43-7 HCAPLUS
CN Acetamide, 2-chloro-N-[[3-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497841-44-8 HCAPLUS
CN Acetamide, 2-chloro-N-[[3-[4-[(3-chloro-4-fluorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



IT **497841-41-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidines as protein tyrosine kinase inhibitors)
RN 497841-41-5 HCAPLUS
CN 2-Propenamide, N-[[4-[4-[[(1R)-1-phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:564221 HCAPLUS
DOCUMENT NUMBER: 129:175920
TITLE: Preparation of nucleosides water soluble adenosine kinase inhibitors
INVENTOR(S): Ugarkar, Bheemarao G.; Erion, Mark D.; Gomez, Galeno Jorge E.
PATENT ASSIGNEE(S): Metabasis Therapeutics, Inc., USA
SOURCE: U.S., 35 pp., Cont.-in-part of U. S. Ser. No. 473,492.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 14
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5795977	A	19980818	US 1996-660532	19960607
WO 9212718	A1	19920806	WO 1992-US515	19920121
W: AU, CA, FI, NO				
AU 665184	B2	19951221	AU 1992-13599	19920121
AU 9213599	A1	19920827		
NO 9302628	A	19930923	NO 1993-2628	19930721
NO 180418	B	19970106		
NO 180418	C	19970416		
US 5646128	A	19970708	US 1994-349125	19941201
US 5658889	A	19970819	US 1994-355836	19941214
US 5726302	A	19980310	US 1995-473492	19950607

PRIORITY APPLN. INFO.:

US 1989-408707	B2	19890918
US 1990-466979	B2	19900118
US 1991-647117	B2	19910123
US 1991-812916	B2	19911223
US 1995-473492	A2	19950607
US 1989-301222	A2	19890124
US 1989-301453	A2	19890124
US 1989-408107	B2	19890915
WO 1992-US515	W	19920121
US 1993-14190	B2	19930203
US 1994-192645	B1	19940203

US 1994-230421 B1 19940419

OTHER SOURCE(S): MARPAT 129:175920

GI



I

AB This invention relates to adenosine kinase inhibitors and to nucleoside analogs I (A1, A2 = independently H, acyl; A1A2 = cyclic carbonate; B = alkenyl, alkyl, alkoxy, aminoalkyl, azidoalkyl, hydroxyalkyl, haloalkyl; D = alkyl, alkenyl; X = carbocyclic or heterocyclic ring, alkyl, alkenyl; Y = C, N; E = nothing or H, halogen; G = H, halogen; p = 0-3), specifically to water soluble, aryl substituted 4-amino-pyrrolo[2,3-d]pyrimidine and pyrazolo[3,4-d]pyrimidine nucleoside analogs having activity as adenosine kinase inhibitors The invention also relates to the preparation and use of these adenosine kinase inhibitors in the treatment of cardiovascular, and cerebrovascular diseases, inflammation and other diseases which can be regulated by increasing the local concentration of adenosine. Thus, 4-N-(4-carboxymethylphenyl)amino-5-phenyl-7-(5-deoxy-1-β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine was prepared and tested as adenosine kinase inhibitor (EC50 = 80 nmol.).

IT **186301-14-4P 186301-15-5P 186301-16-6P**
186301-17-7P 211447-03-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nucleosides water soluble adenosine kinase inhibitors)

RN 186301-14-4 HCAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(5-deoxy-β-D-ribofuranosyl)-N-(4-fluorophenyl)-5-[4-(1-piperazinylmethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186301-15-5 HCAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(5-deoxy-β-D-ribofuranosyl)-5-[4-[(dimethylamino)methyl]phenyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186301-16-6 HCAPLUS
CN Piperazine, 1-[4-[7-(5-deoxy-β-D-ribofuranosyl)-4-[(4-fluorophenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 186301-17-7 HCAPLUS
CN Benzamide, 4-[7-(5-deoxy-β-D-ribofuranosyl)-4-[(4-fluorophenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-N-[2-(diethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 211447-03-9 HCAPLUS
CN Piperazine, 1-[4-[7-(5-deoxy-β-D-ribofuranosyl)-4-[(4-fluorophenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **211447-04-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nucleosides water soluble adenosine kinase inhibitors)
RN 211447-04-0 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[7-[5-deoxy-2,3-O-(1-methylethylidene)-β-D-ribofuranosyl]-4-[(4-fluorophenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzoyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



O

REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:405444 HCAPLUS
DOCUMENT NUMBER: 129:67984
TITLE: Preparation of orally active nucleoside adenosine kinase inhibitors
INVENTOR(S): Ugarkar, Bheemarao G.; Erion, Mark D.; Gomez, Galeno Jorge E.; Castellino, Angelo J.; Browne, Clinton E.
PATENT ASSIGNEE(S): Metabasis Therapeutics, Inc., USA
SOURCE: U.S., 22 pp., Cont.-in-part of U.S. Ser. No. 473,491. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 14
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5763597	A	19980609	US 1996-660506	19960607
WO 9212718	A1	19920806	WO 1992-US515	19920121
W: AU, CA, FI, NO				
AU 665184	B2	19951221	AU 1992-13599	19920121
AU 9213599	A1	19920827		
NO 9302628	A	19930923	NO 1993-2628	19930721
NO 180418	B	19970106		
NO 180418	C	19970416		
US 5646128	A	19970708	US 1994-349125	19941201
US 5658889	A	19970819	US 1994-355836	19941214
US 5721356	A	19980224	US 1995-473491	19950607

PRIORITY APPLN. INFO.:

US 1989-408707	B2	19890918
US 1990-466979	B2	19900118
US 1991-647117	B2	19910123
US 1991-812916	B2	19911223
US 1995-473491	A2	19950607
US 1989-301222	A2	19890124
US 1989-301453	A2	19890124
US 1989-408107	B2	19890915
WO 1992-US515	W	19920121
US 1993-14190	B2	19930203
US 1994-192645	B1	19940203
US 1994-230421	B1	19940419

OTHER SOURCE(S): MARPAT 129:67984
GI



I

AB Orally active nucleoside adenosine kinase inhibitors I (R = alkenyl, alkyl, alkoxyalkyl, aminoalkyl, azidoalkyl, haloalkyl; R1, R2 = independently H, acyl, together as cyclic carbonate; D = halo, alkyl, alkenyl, aryl, aralkyl, alkynyl, haloalkyl, cyano, carboxamido; Y = C, N; G = H, halo; n = 0-3) were prepared as adenosine kinase inhibitors. The invention also relates to the preparation and use of these and other adenosine kinase inhibitors in the treatment of cardiovascular and cerebrovascular diseases, inflammation and other diseases which can be regulated by increasing the local concentration of adenosine.

4-N-(4-ethoxymethylphenyl)amino-5-phenyl-7-(5-deoxy-β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine was prepared and tested as adenosine kinase inhibitor (IC50 = 6 nM) and as anticonvulsant agent (ED50 > 0.5 mg/kg).

IT **186393-57-7P 186393-95-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of orally active nucleoside adenosine kinase inhibitors)

RN 186393-57-7 HCAPLUS

CN Urea, [[4-[7-(5-deoxy-β-D-ribofuranosyl)-4-[(4-fluorophenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186393-95-3 HCAPLUS
CN Benzonitrile, 4-[7-(5-deoxy-β-D-ribofuranosyl)-4-[(4-fluorophenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:147332 HCAPLUS
DOCUMENT NUMBER: 128:192664
TITLE: Preparation of substituted pyrrolopyrimidines as antitumor agents
INVENTOR(S): Traxler, Peter; Bold, Guido; Lang, Marc; Frei, Jorg
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Traxler, Peter; Bold, Guido; Lang, Marc; Frei, Jorg
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
[redacted]	A1	19980226	[redacted]	19970821
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CN 1194647	A	19980930	CN 1996-196640	19960624
CN 1100778	B	20030205		
CA 2262421	AA	19980226	CA 1997-2262421	19970821
AU 9742064	A1	19980306	AU 1997-42064	19970821
AU 720429	B2	20000601		
EP 938486	A1	19990901	EP 1997-940108	19970821
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000516626	T2	20001212	JP 1998-510425	19970821
US 6180636	B1	20010130	US 1999-242592	19990219

PRIORITY APPLN. INFO.:
CH 1996-2071 A 19960823
CH 1995-1976 A 19950706
WO 1997-EP4564 A 19970821

OTHER SOURCE(S): MARPAT 128:192664
GI



I

AB The title compds. [I; n = 0-3; q = 0-1; R = halo, lower alkyl, HOCH2, etc.; one of the radicals R1 and R2 = H, lower alkyl, and the other of the radicals R1 and R2 = (un)substituted Ph, amino-lower alkyl, piperidine-1-carbonyl, etc.], inhibitors of the tyrosine kinase activity of the receptor for the epidermal growth factor (EGF) and c-erbB2kinase and therefore useful as antitumor agents, were prepared and formulated. Thus, hydrogenation of 4-(3-chloroanilino)-6-formyl-7H-pyrrolo[2,3-d]pyrimidine (preparation described) with N-methylpiperazine in the presence of Raney Ni in DMPU, AcOH and MeOH afforded I [R = 3-Cl; R1 = H; R2 = 4-methylpiperazin-1-ylmethyl; q = 0]. Compds. I inhibit EGF-R-PTK activity by 50% (IC50), for example in a concentration of 0.0005-1 μM, especially from 0.001-1 μM. Compds. I are effective at 0.5-2 g/day when

administered to a patient of a body weight of about 70 kg.

IT **203724-12-3P 203724-13-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted pyrrolopyrimidines as antitumor agents)

RN 203724-12-3 HCAPLUS
CN Morpholine, 4-[4-[4-[(3-chlorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]benzoyl]- (9CI) (CA INDEX NAME)



RN 203724-13-4 HCAPLUS
CN Piperazine, 1-[4-[4-[(3-chlorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]benzoyl]-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:204107 HCAPLUS
DOCUMENT NUMBER: 126:199578
TITLE: Preparation of 7H-pyrrolo[2,3-d]pyrimidines as tyrosine protein kinase inhibitors
INVENTOR(S): Traxler, Peter; Bold, Guido; Brill, Wolfgang Karl-Diether; Frei, Joerg

PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.; Traxler, Peter; Bold, Guido; Brill, Wolfgang, Karl-Diether; Frei, Joerg
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9702266	A1	19970123	WO 1996-EP2728	19960624
W: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2224435	AA	19970123	CA 1996-2224435	19960624
AU 9664148	A1	19970205	AU 1996-64148	19960624
AU 707626	B2	19990715		
EP 836605	A1	19980422	EP 1996-923893	19960624
EP 836605	B1	20020206		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9609617	A	19990525	BR 1996-9617	19960624
JP 11508570	T2	19990727	JP 1997-504763	19960624
AT 212993	E	20020215	AT 1996-923893	19960624
PT 836605	T	20020731	PT 1996-923893	19960624
ES 2172670	T3	20021001	ES 1996-923893	19960624
IL 122855	A1	20040831	IL 1996-122855	19960624
PL 188959	B1	20050531	PL 1996-324285	19960624
ZA 9605723	A	19970106	ZA 1996-5723	19960705
TW 472057	B	20020111	TW 1996-85108440	19960712
NO 9705956	A	19980210	NO 1997-5956	19971218
NO 310359	B1	20010625		
US 6140332	A	20001031	US 1998-981877	19980126
HK 1008222	A1	20021018	HK 1998-109298	19980720

PRIORITY APPLN. INFO.:

CH 1995-1976	A	19950706
CH 1995-2498	A	19950901
CH 1995-3198	A	19951110
CH 1996-255	A	19960201
CH 1996-1224	A	19960513
WO 1996-EP2728	W	19960624

OTHER SOURCE(S): MARPAT 126:199578
GI



I

AB The title compds. [I; R = halo, lower alkyl, OH, etc.; R1, R2 = H, (un)substituted Ph, pyridyl, etc.; R1R2 = (un)substituted C4-10 1,4-alkadienylene; R6 = H, lower alkyl, lower alkoxycarbonyl, etc.; q = 0-1; n = 1-3 when q = 0; n = 0-3 when q = 1], which inhibit tyrosine protein kinase and can be used in the treatment of hyperproliferative diseases, for example tumor diseases, were prepared and formulated. Thus, reaction of 4-chloro-6-(pyrid-2-yl)-7H-pyrrolo[2,3-d]pyrimidine with 3-chloroaniline in the presence of DMPU in n-BuOH afforded I [R = 3-Cl; R1 = H; R2 = 2-pyridyl; q = 0]. Compds. I are effective at 0.5-2 g/day in the treatment of an individual having a body weight of about 70 kg.

IT **187724-58-9P 187724-59-0P 187724-60-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 7H-pyrrolo[2,3-d]pyrimidines as tyrosine protein kinase inhibitors)

RN 187724-58-9 HCAPLUS
CN Benzamide, 4-[4-[(3-chlorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 187724-59-0 HCAPLUS
CN Benzamide, 4-[4-[(3-chlorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 187724-60-3 HCAPLUS
CN Benzamide, 3-[4-[(3-chlorophenyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 26 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:121409 HCAPLUS
DOCUMENT NUMBER: 126:131750
TITLE: Preparation of nucleoside analogs as orally active adenosine kinase inhibitors
INVENTOR(S): Ugarkar, Gheemarao G.; Erion, Mark D.; Galeno, Jorge E. Gomez; Castellino, Angelo J.; Browne, Clinton E.
PATENT ASSIGNEE(S): Gensia Inc., USA
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 14
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640706	A1	19961219	WO 1996-US10919	19960607
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
US 5721356	A	19980224	US 1995-473491	19950607
AU 9663958	A1	19961230	AU 1996-63958	19960607
EP 832092	A1	19980401	EP 1996-923451	19960607
EP 832092	B1	20041117		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11507390	T2	19990629	JP 1996-502318	19960607
BR 9608625	A	19991207	BR 1996-8625	19960607
AT 282628	E	20041215	AT 1996-923451	19960607

PRIORITY APPLN. INFO.:	US 1995-473491	A	19950607
	US 1989-408707	B2	19890915
	US 1990-466979	B2	19900118
	US 1991-647117	B2	19910123
	US 1991-812916	B2	19911223
	WO 1996-US10919	W	19960607

OTHER SOURCE(S): MARPAT 126:131750
GI



I

AB Title nucleosides I (A1, A2 = H, acyl, cyclic carbonate; B = alkenyl, alkyl, aminoalkyl, azidoalkyl, haloalkyl; D = halogen, alkyl, alkenyl, aryl, aralkyl, alkynyl, CN, carboxamido; Y = C, N; E = H, halogen, alkyl; G = H, halogen; p = 0-3) were prepared as adenosine kinase inhibitors. The invention also relates to the preparation and use of these and other adenosine kinase inhibitors in the treatment of cardiovascular and cerebrovascular diseases, inflammation, and other diseases which can be regulated by increasing the local concentration of adenosine. Thus, 4-N-(4-methoxyphenyl)amino-3-phenyl-1-(5-azido-5-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine was prepared and showed adenosine kinase inhibition (IC50 = 8 nM) and anticonvulsant activity (i.p. >> 3.4 mg/Kg).

IT **186393-57-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of nucleoside analogs as orally active adenosine kinase inhibitors)

RN 186393-57-7 HCAPLUS

CN Urea, [[4-[7-(5-deoxy-β-D-ribofuranosyl)-4-[(4-fluorophenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **186393-94-2P 186393-95-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nucleoside analogs as orally active adenosine kinase inhibitors)
RN 186393-94-2 HCAPLUS
CN Benzonitrile, 3-[7-(5-deoxy-β-D-ribofuranosyl)-4-[(4-fluorophenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186393-95-3 HCAPLUS
CN Benzonitrile, 4-[7-(5-deoxy-β-D-ribofuranosyl)-4-[(4-fluorophenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 27 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:119216 HCAPLUS
DOCUMENT NUMBER: 126:131749
TITLE: Preparation of water-soluble nucleoside analogs as adenosine kinase inhibitors
INVENTOR(S): Ugarkar, Bheemarao G.; Erion, Mark D.; Galeno, Jorge E. Gomez
PATENT ASSIGNEE(S): Gensia Inc., USA
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 14
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640707	A1	19961219	WO 1996-US10956	19960607
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
US 5726302	A	19980310	US 1995-473492	19950607
AU 9664790	A1	19961230	AU 1996-64790	19960607
EP 836613	A1	19980422	EP 1996-924302	19960607
EP 836613	B1	20050525		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11509181	T2	19990817	JP 1996-502319	19960607
BR 9609011	A	19991214	BR 1996-9011	19960607
AT 296309	E	20050615	AT 1996-924302	19960607

PRIORITY APPLN. INFO.:

US 1995-473492	A	19950607
US 1989-408707	B2	19890918
US 1990-466979	B2	19900118
US 1991-647117	B2	19910123
US 1991-812916	B2	19911223
WO 1996-US10956	W	19960607

OTHER SOURCE(S): MARPAT 126:131749
GI



I

AB This invention relates to adenosine kinase inhibitors and to nucleoside analogs specifically to orally active, substituted 5-aryl pyrrolo[2,3-d] pyrimidine and 3-aryl pyrazolo[3,4-d] pyrimidine nucleoside analogs having

activity as adenosine kinase inhibitors. The invention also relates to the preparation and use of these and other adenosine kinase inhibitors in the treatment of cardiovascular and cerebrovascular disease, inflammation and other diseases which can be regulated by increasing the local concentration of adenosine. Water-soluble nucleoside analogs I [R = (un)substituted aryl; R1,R2 = H, acyl, cyclic carbonate; B = alkenyl, alkyl, ether, aminoalkyl, azidoalkyl; D = halo, alkyl, alkenyl, cyano, carboxamido; E, G = H, halogen] were prepared as adenosine kinase inhibitors. Thus, 4-N-(4-guanidinophenyl)amino-5-phenyl-7-(5-deoxy-1-β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine was prepared as adenosine kinase inhibitor (IC50= 6 nmol) and anticonvulsant (ED50 = 5.0 mg/kg).

IT **186301-14-4P 186301-15-5P 186301-16-6P 186301-17-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of water-soluble nucleoside analogs as adenosine kinase inhibitors)

RN 186301-14-4 HCAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(5-deoxy-β-D-ribofuranosyl)-N-(4-fluorophenyl)-5-[4-(1-piperazinylmethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186301-15-5 HCAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(5-deoxy-β-D-ribofuranosyl)-5-[4-[(dimethylamino)methyl]phenyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186301-16-6 HCAPLUS
CN Piperazine, 1-[4-[7-(5-deoxy-β-D-ribofuranosyl)-4-[(4-fluorophenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 186301-17-7 HCAPLUS
CN Benzamide, 4-[7-(5-deoxy-β-D-ribofuranosyl)-4-[(4-fluorophenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-N-[2-(diethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl